Polymyxin E Synthetase Gene Cluster Engineering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing polymyxin E, such as fermentation of bacterial strains, result in low purity and high toxicity due to the cationic nature of the molecule and impurities, necessitating the development of new production techniques to create purer and less toxic variants.
Innovation Solution
Isolation and characterization of a gene cluster from Paenibacillus alvei that encodes for polymyxin E synthetases, specifically the PmxA and PmxE enzymes, allowing for genetic engineering to produce polymyxin E with reduced toxicity and improved purity by modifying the peptide structure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If polymyxin E is produced by fermentation of bacterial strains, then the molecule can be obtained, but the purity is low and toxicity is high due to impurities and cationic nature
Solution Approach 1:
The invention divides the polymyxin E molecule into modular components by identifying and isolating specific gene clusters (pmx operon) that encode individual synthetase enzymes (PmxA, PmxB, PmxC, PmxD, PmxE). Each enzyme corresponds to a specific module in the non-ribosomal peptide synthetase system, allowing independent manipulation and optimization of each segment to improve purity while maintaining or reducing toxicity through precise structural control
Solution Approach 2:
The invention changes the chemical parameters of the polymyxin E molecule by modifying the amino acid sequence and peptide structure through genetic engineering of the synthetase genes. Specifically, the patent describes creating variants with altered cationic charge distribution by modifying basic amino acid residues, thereby reducing toxicity while maintaining antimicrobial activity. The purification process also changes physical parameters by removing impurities to achieve higher purity
2Object-generated harmful factors
If the peptide structure of polymyxin E is modified to reduce cationic charges, then toxicity is reduced, but antimicrobial activity may be affected
Solution Approach 1:
The invention applies local quality changes by selectively modifying specific amino acid residues at particular positions in the polymyxin E peptide chain rather than uniformly altering the entire molecule. The patent describes targeted modifications of basic amino acids (lysine, arginine, histidine) at specific positions to reduce cationic charges in regions responsible for toxicity, while preserving the cationic residues essential for membrane binding and antimicrobial activity. This localized approach allows differential optimization of toxicological and therapeutic properties
Solution Approach 2:
The invention employs feedback mechanisms through the modular NRPS system where each synthetase module contains adenylation (A), thiolation (T), and condensation (C) domains that work in sequence. The epimerization domain (E) in PmxE provides feedback control by converting L-Dab to D-Dab at position 3, which influences the overall conformation and charge distribution of the molecule. This modular feedback system allows precise control over the final peptide structure to balance toxicity and activity
Data Source
AI summary
PmxA synthetase involved in polymyxin E synthesis, comprising four adenylation sites, characterized in that the second adenylation site has at least 90% identity with the peptide sequence SEQ ID NO 1:VTEAEKADLLGRFNDTTTEFPRGKTLIQLFEEQVERIPDAAAITLNEQELTYRELNERVNRLARTLRSHGISKGRLVAILAERSIEMVVGMLAAHKAGAAYVPIDPEYPEERIRFLIEDSGGQVMLTQSRLRERLAGSDPVILLDDESFYHEDGTNLNTGIEATDLACVIYTSGTTGKPKGNPVSHRNIVRVVQNTNYIDITERDHVLQLSSYSFDGATFDIFGALTNGARLVLVPYETLLEIGRLADLIQRERISVMFITTAFFNILVDVNVDCLRDVRAILFGGERVSVGHVRKALAHIGPGRLNHVYGPTESTVYTTYLPVDFVDELAVTVPIGRPISNTTVYIVDSRNKLLPIGVAGELCVGGEGLVRGYNNRPELTAEKFVDNPFVPGERMYRTGDLAKWLPDGTIEYVGRTDDQVKIRGFRIELGEIEAQLQKVEGIRKTTVFARENASGEKQLCAYYEADCELPAAELKSVLSKELPAYMIPAYLIQLERLPLTTNGKVDRRSLPAPEESLQPGGG,the underlined amino acids DGFFLGVVYK being conserved and forming a binding pocket specific for a leucine, isoleucine or valine residue.